Effects of chronic glucagon-like peptide-2 therapy during weaning in neonatal pigs

Regulatory Peptides

Volumn 188, Issue , 2014, Pages 70-80

  Sigalet, David L ^a   de Heuvel, Elaine ^a   Wallace, Laurie ^a   Bulloch, Estrella ^a   Turner, Justine ^b   Nation, Patrick ^b   Wizzard, Pamela R ^b   Hartmann, Bollette ^c   Assad, Meena ^a   Holst, Jens J ^c  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Crypt cell proliferation; DPP IV; Feeding behavior; Ki 67; Nutrient absorption

Indexed keywords

CASPASE 3; GLUCAGON LIKE PEPTIDE 2; GLUCAGON LIKE PEPTIDE 2 RECEPTOR; HORMONE RECEPTOR; KI 67 ANTIGEN; MESSENGER RNA; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EUTHANASIA; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; AUTOPSY; BODY GROWTH; CELL PROLIFERATION; COLON; CONTROLLED STUDY; CRYPT CELL; DRUG MECHANISM; DRUG TOLERABILITY; FEMALE; FOOD INTAKE; GASTROINTESTINAL TRACT; GENE EXPRESSION; HISTOPATHOLOGY; INFANCY; INTESTINE CRYPT; INTESTINE VILLUS; LARGE INTESTINE; NEUROLOGIC EXAMINATION; NEWBORN; NONHUMAN; NUCLEOTIDE SEQUENCE; ORGAN WEIGHT; PHYSICAL DEVELOPMENT; PIGLET; PRIORITY JOURNAL; SMALL INTESTINE; SWINE; TREATMENT DURATION; WEANING; WEIGHT GAIN;

CRYPT CELL PROLIFERATION; DPP-IV; FEEDING BEHAVIOR; KI-67; NUTRIENT ABSORPTION;

ANIMALS; ANIMALS, NEWBORN; DRUG EVALUATION, PRECLINICAL; GASTROINTESTINAL AGENTS; GASTROINTESTINAL TRACT; GLUCAGON-LIKE PEPTIDE 2; ORGAN SIZE; SUS SCROFA; WEANING; WEIGHT GAIN;

EID: 84892645723     PISSN: 01670115     EISSN: 18731686     Source Type: Journal    
DOI: 10.1016/j.regpep.2013.12.006     Document Type: Article

References (41)

1. Drucker D.J. Biological actions and therapeutic potential of the glucagon-like peptides. Gastroenterology February 2002, 122(2):531-544.
2. Orskov C., Holst J.J., Knuhtsen S., et al. Glucagon-like peptide GLP-1 and GLP-2, predicted products of the glucagon gene are secreted separately from pig small intestine but not pancreas. Endocrinology 1986, 119(4):1467-1475.
3. Brubaker P.L., Anini Y. Direct and indirect mechanisms regulating secretion of glucagon-like peptide-1 and glucagon-like peptide-2. Can J Physiol Pharmacol November 2003, 81(11):1005-1012.
4. Drucker D.J., Erlich P., Asa S.L., Brubaker P.L. Induction of intestinal epithelial proliferation by glucagon-like peptide 2. Proc Natl Acad Sci U S A July 23 1996, 93(15):7911-7916.
5. Guan X., Karpen H.E., Stephens J., Bukowski J.T., Niu S., Zhang G., Stoll B., Finegold M.J., Holst J.J., Hadsell D., Nichols B.L., Burrin D.G. GLP-2 receptor localizes to enteric neurons and endocrine cells expressing vasoactive peptides and mediates increased blood flow. Gastroenterology January 2006, 130(1):150-164.
6. Orskov C., Hartmann B., Poulsen S.S., Thulesen J., Hare K.J., Holst J.J. GLP-2 stimulates colonic growth via KGF, released by subepithelial myofibroblasts with GLP-2 receptors. Regul Pept January 15 2005, 124(1-3):105-112.
7. Yusta B., Huang L., Munroe D., Wolff G., Fantaske R., Sharma S., Demchyshyn L., Asa S.L., Drucker D.J. Enteroendocrine localization of GLP-2 receptor expression in humans and rodents. Gastroenterology September 2000, 119(3):744-755.
8. de Heuvel E., Wallace L., Sharkey K.A., Sigalet D.L. Glucagon-like peptide 2 induces vasoactive intestinal polypeptide expression in enteric neurons via phophatidylinositol 3-kinase-gamma signaling. Am J Physiol Endocrinol Metab October 15 2012, 303(8):E994-E1005.
9. Schmidt P.T., Naslund E., Gryback P., Jacobsson H., Hartmann B., Holst J.J., Hellstrom P.M. Peripheral administration of GLP-2 to humans has no effect on gastric emptying or satiety. Regul Pept November 15 2003, 116(1-3):21-25.
10. Tang-Christensen M., Larsen P.J., Thulesen J., Romer J., Vrang N. The proglucagon-derived peptide, glucagon-like peptide-2, is a neurotransmitter involved in the regulation of food intake. Nat Med July 2000, 6(7):802-807.
11. Dube P.E., Forse C.L., Bahrami J., Brubaker P.L. The essential role of insulin-like growth factor-1 in the intestinal tropic effects of glucagon-like peptide-2 in mice. Gastroenterology August 2006, 131(2):589-605.
12. Sigalet D.L., Wallace L.E., Holst J.J., Martin G.R., Kaji T., Tanaka H., Sharkey K.A. Enteric neural pathways mediate the anti-inflammatory actions of glucagon-like peptide 2. Am J Physiol Gastrointest Liver Physiol 2007, 293(6):G211-G221.
13. Amin H., Holst J.J., Hartmann B., Wallace L., Wright J., Sigalet D.L. Functional ontogeny of the proglucagon-derived peptide axis in the premature human neonate. Pediatrics January 2008, 121(1):e180-e186.
14. Petersen Y.M., Burrin D.G., Sangild P.T. GLP-2 has differential effects on small intestine growth and function in fetal and neonatal pigs. Am J Physiol Regul Integr Comp Physiol December 2001, 281(6):R1986-R1993.
15. Petersen Y.M., Hartmann B., Holst J.J., Huerou-Luron I., Bjornvad C.R., Sangild P.T. Introduction of enteral food increases plasma GLP-2 and decreases GLP-2 receptor mRNA abundance during pig development. J Nutr June 2003, 133(6):1781-1786.
16. Martin G.R., Wallace L.E., Sigalet D.L. Glucagon-like peptide-2 induces intestinal adaptation in parenterally fed rats with short bowel syndrome. Am J Physiol Gastrointest Liver Physiol June 2004, 286(6):G964-G972.
17. Scott R.B., Kirk D., MacNaughton W.K., Meddings J.B. GLP-2 augments the adaptive response to massive intestinal resection in rat. Am J Physiol November 1998, 275(5 Pt. 1):G911-G921.
18. Jeppesen P.B., Perkiewicz M., Seidner D.L., O'Keefe S., Heinze H., Joelsson B. Teduglutide, a novel analogue of glucagon-like peptide 2 (GLP-2), is effective and safe in reducing parenteral support volume in short bowel syndrome-intestinal failure subjects: results from a 24-week, placebo-controlled phase 3 trial (STEPS). Gastroenterology 2011, 140(5, Supplement 1):S146.
19. Jeppesen P.B., Gilroy R., Pertkiewicz M., Allard J.P., Messing B., O'Keefe S.J. Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome. Gut July 2011, 60(7):902-914.
20. Sangild P.T. Gut responses to enteral nutrition in preterm infants and animals. Exp Biol Med (Maywood) December 2006, 231(11):1695-1711.
21. Henriksen D.B., Alexandersen P., Hartmann B., Adrian C.L., Byrjalsen I., Bone H.G., Holst J.J., Christiansen C. Four-month treatment with GLP-2 significantly increases hip BMD: a randomized, placebo-controlled, dose-ranging study in postmenopausal women with low BMD. Bone November 2009, 45(5):833-842.
22. Jeppesen P.B., Hartmann B., Thulesen J., Graff J., Lohmann J., Hansen B.S., Tofteng F., Poulsen S.S., Madsen J.L., Holst J.J., Mortensen P.B. Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon. Gastroenterology March 2001, 120(4):806-815.
23. Jeppesen P.B., Lund P., Gottschalck I.B., Nielsen H.B., Holst J.J., Mortensen J., Poulsen S.S., Quistorff B., Mortensen P.B. Short bowel patients treated for two years with glucagon-like Peptide 2: effects on intestinal morphology and absorption, renal function, bone and body composition, and muscle function. Gastroenterol Res Pract 2009, 2009:616054.
24. Jeppesen P.B., Lund P., Gottschalck I.B., Nielsen H.B., Holst J.J., Mortensen J., Poulsen S.S., Quistorff B., Mortensen P.B. Short bowel patients treated for two years with glucagon-like peptide 2 (GLP-2): compliance, safety, and effects on quality of life. Gastroenterol Res Pract 2009, 2009:425759.
25. Petroianu G., Hardt F., Toomes M., Bergler W., Rufer R. High-dose intravenous paraoxon exposure does not cause organophosphate-induced delayed neuropathy (OPIDN) in mini pigs. J Appl Toxicol July 2001, 21(4):263-268.
26. Hartmann B., Johnsen A.H., Orskov C., Adelhorst K., Thim L., Holst J.J. Structure, measurement, and secretion of human glucagon-like peptide-2. Peptides January 2000, 21(1):73-80.
27. Hartmann B., Harr M.B., Jeppesen P.B., Wojdemann M., Deacon C.F., Mortensen P.B., Holst J.J. In vivo and in vitro degradation of glucagon-like peptide-2 in humans. J Clin Endocrinol Metab August 2000, 85(8):2884-2888.
28. Kaji T., Tanaka H., Redstone H., Wallace L., Holst J.J., Sigalet D.L. Temporal changes in the intestinal growth promoting effects of glucagon-like peptide 2 following intestinal resection. J Surg Res 2009, 152:271-280.
29. Kaji T., Tanaka H., Holst J.J., Redstone H., Wallace L., de H.E., Sigalet D.L. The effects of variations in dose and method of administration on glucagon like peptide-2 activity in the rat. Eur J Pharmacol October 31 2008, 596(1-3):138-145.
30. Sigalet D.L., Bawazir O., Martin G.R., Wallace L.E., Zaharko G., Miller A., Zubaidi A. Glucagon-like peptide-2 induces a specific pattern of adaptation in remnant jejunum. Dig Dis Sci September 2006, 51(9):1557-1566.
31. Burrin D.G., Stoll B., Guan X., Cui L., Chang X., Holst J.J. Glucagon-like peptide 2 dose-dependently activates intestinal cell survival and proliferation in neonatal piglets. Endocrinology January 2005, 146(1):22-32.
32. Burrin D.G., Stoll B., Guan X., Cui L., Chang X., Hadsell D. GLP-2 rapidly activates divergent intracellular signaling pathways involved in intestinal cell survival and proliferation in neonatal piglets. Am J Physiol Endocrinol Metab January 2007, 292(1):E281-E291.
33. Hua Z., Turner J.M., Sigalet D.L., Wizzard P.R., Nation N., Mager D.R., Ball R.O., Pencharz P.M., Wales P.W. Role of glucagon-like peptide-2 deficiency in neonatal short bowel syndrome using neonatal piglets. Pediatr Res Jun 2013, 73(6):742-749. Band, [Suger. Pediatr Res 2013;73:742-9].
34. Lovshin J., Yusta B., Iliopoulos I., Migirdicyan A., Dableh L., Brubaker P.L., Drucker D.J. Ontogeny of the glucagon-like peptide-2 receptor axis in the developing rat intestine. Endocrinology November 2000, 141(11):4194-4201.
35. Mentlein R. Dipeptidyl-peptidase IV, (CD26)-role in the inactivation of regulatory peptides. Regul Pept 1999, 85:9-24.
36. Bremholm L., Hornum M., Andersen U.B., Hartmann B., Holst J.J., Jeppesen P.B. The effect of glucagon-like peptide-2 on mesenteric blood flow and cardiac parameters in end-jejunostomy short bowel patients. Regul Pept June 7 2011, 168(1-3):32-38.
37. Meier J.J., Nauck M.A., Pott A., Heinze K., Goetze O., Bulut K., Schmidt W.E., Gallwitz B., Holst J.J. Glucagon-like peptide 2 stimulates glucagon secretion, enhances lipid absorption, and inhibits gastric acid secretion in humans. Gastroenterology January 2006, 130(1):44-54.
38. Sigalet D., Boctor D., Brindle M., Lam V., Robertson M. Elements of successful intestinal rehabilitation. J Pediatr Surg January 2011, 46(1):150-156.
39. Sigalet D.L. Short bowel syndrome in infants and children: an overview. Semin Pediatr Surg May 2001, 10(2):49-55.
40. Iakoubov R., Lauffer L.M., Trivedi S., Kim Y.I., Brubaker P.L. Carcinogenic effects of exogenous and endogenous glucagon-like peptide-2 in azoxymethane-treated mice. Endocrinology September 2009, 150(9):4033-4043.
41. Trivedi S., Wiber S.C., El-Zimaity H.M., Brubaker P.L. Glucagon-like peptide-2 increases dysplasia in rodent models of colon cancer. Am J Physiol Gastrointest Liver Physiol April 15 2012, 302(8):G840-G849.